Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin pharmacokinetics by maternal BMI for postpartum haemorrhage prophylaxis
ACTRN12617000176369Phase 4Withdrawn
- Sponsor
- Monash Health
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of oxytocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Monash Health. Primary endpoints: Relationship between maternal BMI and oxytocin pharmacokinetics, Absolute bioavailability and 7 more. Planned start Jan 2023; status: withdrawn.
02
Drugs
oxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on ACTRN12617000176369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000176369.